Literature DB >> 3319500

Role of cephalosporins in gonorrhoea and other sexually transmitted diseases.

I Phillips1.   

Abstract

Cephalosporins have a role in the treatment of gonorrhoea, and especially infections caused by strains that are penicillin-resistant, either because they produce plasmid-mediated beta-lactamase or they have chromosomally mediated diminished permeability or modified penicillin-binding proteins. Although none of the oral or Group I agents are useful, most of the Group II, III and IV agents are, and especially cefuroxime, cefotaxime, ceftriaxone and cefoxitin. In addition to uncomplicated urethral, cervical or rectal infections, appropriate regimens are also effective for the treatment of pharyngeal infections, disseminated infections and gonococcal ophthalmia. The cephalosporins have no clear role in the treatment of syphilis, granuloma inguinale, Mycoplasma or chlamydial infections or bacterial vaginosis, but ceftriaxone may be effective in chancroid, and cefoxitin in combination with an antichlamydial agent (such as a tetracycline) might be used for the treatment of pelvic inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319500     DOI: 10.2165/00003495-198700342-00013

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  94 in total

1.  Sexually transmitted disease surveillance in Britain--1984. Communicable Disease Surveillance Centre.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-11

2.  The treatment of early syphilis with cephaloridine.

Authors:  A Gonzalez-Ochoa; J B Moreno
Journal:  Postgrad Med J       Date:  1967-08       Impact factor: 2.401

Review 3.  Microbiological investigation of cephalosporins.

Authors:  J M Hamilton-Miller
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Single 1 g dose of cefotaxime in the treatment of infections due to penicillinase-producing strains of Neisseria gonorrhoeae.

Authors:  G A de Koning; D Tio; J A van den Hoek; B van Klingeren
Journal:  Br J Vener Dis       Date:  1983-04

5.  In-vitro activity of 21 antimicrobial agents against Neisseria gonorrhoeae in Brussels.

Authors:  B Gordts; R Vanhoof; J M Hubrechts; R Dierickx; H Coignau; J P Butzler
Journal:  Br J Vener Dis       Date:  1982-02

6.  Association of auxotypes of Neisseria gonorrhoeae and susceptibility to penicillin G, spectinomycin, tetracycline, cefaclor, cefoxitin, and moxalactam.

Authors:  R C Noble; M C Parekh
Journal:  Sex Transm Dis       Date:  1983 Jan-Mar       Impact factor: 2.830

7.  Dose-ranging study of ceftriaxone for uncomplicated gonorrhea in men.

Authors:  H H Handsfield; V L Murphy; K K Holmes
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

8.  Treatment of gonorrhea: comparison of cefotaxime and penicillin.

Authors:  M L Simpson; M Y Khan; Y Siddiqui; R P Gruninger; D I Wigren
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

9.  Treatment of uncomplicated gonorrhea with cefotaxime.

Authors:  H H Handsfield; K K Holmes
Journal:  Sex Transm Dis       Date:  1981 Jul-Sep       Impact factor: 2.830

10.  Polygenes and modifier genes for tetracycline and penicillin resistance in Neisseria gonorrhoeae.

Authors:  P F Warner; L J Zubrzycki; M Chila
Journal:  J Gen Microbiol       Date:  1980-03
View more
  4 in total

Review 1.  Treatment of respiratory tract infections with cephalosporin antibiotics.

Authors:  R Finch
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 2.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 3.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 4.  Cephalosporin-probenecid drug interactions.

Authors:  G R Brown
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.